Hyperkalemia News and Research

RSS

Why keto appears to lower blood pressure for some people but not others

A narrative review finds that ketogenic diets may modestly lower blood pressure through weight loss, reduced visceral fat, improved insulin sensitivity, fluid and electrolyte shifts, and anti-inflammatory effects. However, effects vary across studies, long-term cardiovascular evidence remains limited, and diet quality, hydration, electrolyte balance, and medication monitoring are important.

17 Aug 2026

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

5 Jun 2026

American Heart Association's 9 diet rules to lower heart disease risk

The AHA's dietary guidance emphasizes food choices over fad diets to reduce heart disease risk and improve cardiovascular health across all life stages.

2 Apr 2026

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Salt substitutes may lower stroke recurrence and death risk

Research indicates that salt substitutes reduce stroke recurrence and death risk, offering a safe dietary intervention for improving stroke patient outcomes.

7 Feb 2025

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or both, offering potential for shorter and more tolerable tuberculosis treatment regimens.

1 Dec 2024

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes

An intensive treatment approach to lowering high systolic blood pressure in people with Type 2 diabetes led to a reduced risk of heart attack, stroke, heart failure and death due to cardiovascular disease when compared to a standard treatment approach, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure

MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.

3 Sep 2024

$FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction$

FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

$Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions$

Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

$Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction$

Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial led by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.

2 Sep 2024

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

There was no difference in major post-operative complications in patients who continued vs. stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Hemp seed protein shows promise in lowering blood pressure

A study in The American Journal of Clinical Nutrition shows that hemp seed protein and its bioactive peptide can significantly lower blood pressure in mildly hypertensive adults, offering a potential dietary intervention for managing hypertension.

7 May 2024

How do acetylsalicylic acid and warfarin interact with various nutrients?

45 drug-nutrient interactions (DNIs) that modify micro-nutritional status, particularly focusing on how acetylsalicylic acid (ASA) and warfarin may affect patients through various mechanisms.

28 Mar 2024

New RNA therapy zilebesiran shows promise in lowering blood pressure

Zilebesiran, an RNA interference therapeutic, significantly reduces blood pressure in hypertension patients with a favorable safety profile, offering a potential biannual treatment option.

19 Feb 2024

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria - albumin in urine, a sign of kidney damage - for 50% of participants.

15 Dec 2023

Finerenone: A promising therapeutic option for cardiovascular diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mineralocorticoid receptor antagonists (MRA) have significant therapeutic effects on heart failure, hypertension, chronic kidney disease and primary aldosteronism.

11 Oct 2023

TPP may be an underrecognized cause of paralysis in young Hispanic men

Thyrotoxic periodic paralysis (TPP), a rare neurological condition causing limbs to go limp, may be an underrecognized cause of paralysis in young Hispanic men, a review of data by UT Southwestern Medical Center endocrinologists shows.

8 May 2023

Eating vegetables and fruits every day may reduce all-cause mortality in patients with CKD

A new study of Japanese patients with and without CKD found that a lower frequency of vegetable and fruit intake was associated with a higher risk of death regardless of CKD status.

27 Feb 2023

Hyperkalemia News and Research

Why keto appears to lower blood pressure for some people but not others

Major trials show finerenone preserves kidney function beyond diabetes

American Heart Association's 9 diet rules to lower heart disease risk

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Salt substitutes may lower stroke recurrence and death risk

Quabodepistat combo shows promise for safer, faster tuberculosis treatment

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes

Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure

FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions

Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

Hemp seed protein shows promise in lowering blood pressure

How do acetylsalicylic acid and warfarin interact with various nutrients?

New RNA therapy zilebesiran shows promise in lowering blood pressure

Experimental drug paired with a standard-care medication offers hope for kidney disease patients

Finerenone: A promising therapeutic option for cardiovascular diseases

TPP may be an underrecognized cause of paralysis in young Hispanic men

Eating vegetables and fruits every day may reduce all-cause mortality in patients with CKD

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News